Dysregulated miR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes

N E Corral-Fernández1, M Salgado-Bustamante, M E Martínez-Leija

  • 1Laboratorio de Inmunología y Biología Celular y Molecular, Facultad de Ciencias Químicas, UASLP, San Luis Potosí, SLP, México.

Insights

Decreased levels of miR-155 and miR-146a in peripheral blood mononuclear cells (PBMC) were observed in type 2 diabetes (T2D) patients. These microRNA (miRNA) changes correlate with metabolic control indicators like HbA1c and BMI.

Area of Science:

  • Molecular Biology
  • Immunology
  • Endocrinology

Background:

  • MicroRNAs (miRNAs) regulate gene expression and are implicated in diseases like cancer and autoimmune disorders.
  • In immune cells, miRNA expression is modulated by cytokines and linked to inflammation.
  • Altered miRNA levels are increasingly recognized in metabolic diseases.

Purpose of the Study:

  • To investigate the expression levels of miR-155 and miR-146a in peripheral blood mononuclear cells (PBMC) of patients with type 2 diabetes (T2D).
  • To explore the association between these miRNA levels and clinical parameters of T2D, including metabolic control.

Main Methods:

  • Real-time PCR was used to analyze miR-155 and miR-146a expression in PBMC from T2D patients (n=20) and controls (n=20).
  • Enzyme-linked immunosorbent assay (ELISA) measured IL-1β and IL-6 levels.
  • Statistical analyses, including three-dimensional variable association, were employed.

Main Results:

  • Basal expression of miR-155 and miR-146a was significantly decreased in T2D patients compared to controls.
  • miRNA levels correlated with age, gender, HbA1c, glucose, and BMI, but not with therapeutic treatment.
  • Stimulated miR-155 expression showed correlations with triglycerides (TG), HbA1c, glucose, and BMI.

Conclusions:

  • Downregulated miR-155 and miR-146a expression in PBMC may be associated with type 2 diabetes.
  • The observed alterations in miR-155 and miR-146a levels suggest a potential role in T2D pathogenesis, particularly concerning metabolic dysregulation.

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...